Key Takeaway:
- U.S. regulators plan to loosen peptide restrictions, potentially expanding legal access and reshaping the wellness treatment market.
- Hims & Hers stock surges as clearer regulations boost investor confidence in telehealth expansion into peptides.
- Safety concerns remain due to limited clinical research and ongoing regulatory uncertainty surrounding peptide therapies.
Hims & Hers Health shares jump on Wednesday after U.S. health officials move to loosen restrictions on several peptides, boosting expectations that telehealth companies may soon expand into the fast-growing wellness treatment market.
U.S. Officials Move To Reassess Peptide Rules
Shares of telehealth company Hims & Hers Health rose sharply on Wednesday after U.S. health regulators announced steps to reconsider restrictions on popular peptide therapies, signaling a potential shift in oversight of the emerging health trend.
Health and Human Services Secretary Robert F. Kennedy Jr. says the federal government plans to relax regulations on 12 peptides restricted in 2023 due to safety concerns. The Food and Drug Administration also schedules a summer meeting to review whether seven peptides can legally be produced by compounding pharmacies.
The moves could enable a wider distribution of peptide-based treatments, which are increasingly promoted for muscle recovery, skin health, and metabolic support.
Hims & Hers previously told investors in February that it is preparing for “future categories like peptides.” Following Wednesday’s announcement, the Hims & Hers Stock closed up 13.7% and climbed another 4% in after-hours trading.
“The FDA’s plans to more clearly define the regulatory status of several peptides is an important step toward moving these treatments out of the gray market and into more trusted channels overseen by vetted healthcare professionals,” Chief Medical Officer Pat Carroll says in a statement.
Telehealth Firms Position For Growing Wellness Market
Peptides are short chains of amino acids that signal biological activity in the body. Compounds such as BPC-157 are widely discussed for muscle recovery, while GHK-Cu is marketed for skin improvement.
Interest in peptides expands rapidly among fitness enthusiasts and online biohacking communities, where social media users frequently discuss personalized “stacks” of therapies. Kennedy himself recently told podcaster Joe Rogan that he has experimented with peptide treatments.
Some widely prescribed medications already fall into the peptide category, including GLP-1 weight-loss drugs such as Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. Reinforcing the broader market relevance tied to Hims & Hers Stock.
Industry analysts say clearer federal guidance could legitimize a market that currently operates in regulatory uncertainty.
“The growth of the peptide industry also exposes a credibility gap: Patients sometimes trust telehealth startups and online pharmacies over clinicians,” consultants at Kaufman Hall write in a note distributed by investment firm William Blair earlier this month. “Regulation alone is powerless to bridge that gap; the market has spoken.”
Safety Concerns And Competition Remain
Despite growing popularity, many peptides remain neither approved drugs nor dietary supplements, and clinical research on long-term human effects is limited. Regulators previously tightened rules amid concerns about quality control and unverified health claims.
Public health experts warn that easier access could increase demand before sufficient scientific evidence is established. Questions also persist about sourcing, manufacturing standards, and patient supervision.
Hims & Hers Stock is not alone in pursuing the opportunity. Digital health company Noom recently acquired a pharmacy already producing certain peptides, signaling broader competition among telehealth and wellness platforms.
“Whether people are tracking food intake, monitoring sleep, or asking about peptide therapies, they’re expressing the same underlying shift: from reactive to proactive,” Noom Chief Medical Officer Jeffrey Egler says in an email statement. “The tools and therapies change, but the underlying instinct remains.”
Investors appear to view regulatory clarity as a catalyst for expansion across digital healthcare companies seeking new revenue streams beyond traditional telemedicine services.
Federal regulators are expected to provide additional guidance after the FDA’s upcoming review meeting, which industry leaders say could determine how quickly peptide therapies move into mainstream medical channels.
